The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 17 of the 41 sources its claims cite were checked for support.
A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality
Open accessAbstract
Objective: To assess the efficacy and safety of Vortioxetine and Escitalopram in improving cognition in patients with major depressive disorder (MDD). Methods: At baseline, 131 MDD patients and 70 healthy controls completed the Hamilton Depression Scale (HAMD-17), Hamilton Anxiety Scale (HAMA), Snaith-Hamilton Pleasure Scale (SHAPS) and MATRICS Consensus Cognitive Battery (MCCB). Patients with MDD were randomly divided into Vortioxetine (n = 62) and Escitalopram (n = 69) groups with an 8-week follow-up research. ANOVA for repeated measurement was utilized to compare the efficacy of Vortioxetine and Escitalopram. Results: The total scores of HAMD-17, HAMA and SHAPS scales had statistical difference between MDD cases and healthy controls (P < 0.001) at baseline. After 8 weeks of treatment, the scale scores of the HAMD-17, HAMA and SHAPS had lowered in both groups, with no statistical difference between two groups (P > 0.05). At baseline, MDD patients had defects in Speed of Processing, Attention Vigilance, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition, compared with healthy controls. After 8 weeks of treatment with Vortioxetine or Escitalopram, the patients had improved in the aspects of cognitive functions above except Social Cognition. Numerical improvements of MCCB scale were found in the two groups, P > 0.05. Most adverse events were mild or moderate, with nausea being the most common adverse event. Conclusion: Both Vortioxetine and Escitalopram can improve the mental status and cognitive functions in MDD patients, with mild or moderate adverse events. Trial Registration: www.chictr.org.cn, identifier: ChiCTR1900024858.
Overview
CoChat Summary
TL;DR
In this 8-week randomized active-controlled trial in Chinese Han patients with MDD, vortioxetine and escitalopram both improved depressive/anxiety/pleasure symptoms and several cognitive domains, with no statistically significant between-drug differences. Adverse events were mostly mild or moderate, with nausea most common.
Key findings
- At baseline, MDD patients differed from healthy controls on HAMD-17, HAMA, and SHAPS total scores (P < 0.001) and on MCCB domains including Speed of Processing, Attention Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition (all P < 0.05).
- After 8 weeks, HAMD-17 (F = 209.638, P < 0.001), HAMA (F = 122.323, P < 0.001), and SHAPS (F = 13.907, P < 0.001) scores decreased over time in both groups, with no between-group difference at baseline, 2, 4, or 8 weeks (all P > 0.05) and no drug-by-time interaction (P > 0.05).
- Cognitive improvements: vortioxetine improved Attention Vigilance (45.15 vs 50.31), Speed of Processing (39.73 vs 47.65), Working Memory (39.78 vs 45.22), Verbal Learning (40.26 vs 47.19), and Reasoning and Problem Solving (41.70 vs 48.67) (P1 < 0.05); escitalopram improved Speed of Processing (41.63 vs 48.77), Attention Vigilance (44.39 vs 47.84), Verbal Learning (43.23 vs 50.00), Visual Learning (43.42 vs 49.63), and Reasoning and Problem Solving (43.56 vs 49.07) (P2 < 0.05). No between-group MCCB differences were found after 8 weeks (all P3 > 0.05).
- Safety: 58 TEAEs occurred, 33 (53.2%) with vortioxetine and 25 (36.2%) with escitalopram; nausea was most common, in 22 (35.5%) vortioxetine and 13 (18.8%) escitalopram patients. Most adverse events were mild or moderate; no deaths or serious adverse events occurred.
Methods
- Randomized, active-controlled, 8-week head-to-head study at the First Affiliated Hospital, College of Medicine, Zhejiang. A total of 131 MDD patients were randomized to vortioxetine (n = 62) or escitalopram (n = 69); 70 healthy controls were matched by age, sex, and years of education. Inclusion required age 18–45, DSM-5 MDD, HAMD-17 ≥ 17, Han nationality, right-handedness, and junior high school education or above.
- Assessments included HAMD-17 as primary efficacy measure, HAMA and SHAPS as secondary efficacy measures, MCCB for cognition at baseline and week 8, and TEAEs for safety. Randomization used a computer-generated scheme stratified by center; efficacy/safety assessors were blind to treatment.
- Analyses used ITT (all randomized patients receiving ≥1 dose and ≥1 postbaseline HAMD-17 assessment) and PP sets; repeated-measures mixed-effect models/ANOVA compared groups over time, with LOCF for HAMD-17 and SPSS 21.0.
Limitations
- The paper states a relatively high attrition rate and small sample size, possibly worsened by COVID-19 restrictions, limited access to vortioxetine in smaller cities, and higher vortioxetine price; it also notes possible low sensitivity of HAMD-17, HAMA, SHAPS, and MCCB, a short 8-week treatment period, and no inclusion of biomarkers such as plasma factors, intestinal flora, or MRI.
- Evident from the text: dropout was differential by group (31/62 vortioxetine vs 47/69 escitalopram completed 8 weeks), and cognitive comparisons used the smaller PP set (31 vs 47), which may reduce power and bias between-group cognitive conclusions.
- Evident from the text: despite randomization, baseline Working Memory MCCB scores differed significantly between the vortioxetine and escitalopram groups (P < 0.01).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
12 Valid · 1 Not valid · 17 Not checked · 37 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The incidence rate is similar to that of previous clinical studies at around 30%.17,34”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Discussion
What the sources say
- Disputedcites [17] Mahableshwarkar, 2015, Psychopharmacology sourceExperimental — accuracy not yet measured
Table 3 (Discussion; page unavailable) reports that any treatment-emergent adverse event occurred in 73.5% and 81.2% of the two vortioxetine groups, not around 30%. Nausea occurred in 35.4% and 33.1%, but that is one specific adverse event, not the overall incidence claimed. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [34] Alvarez, 2012, Int J Neuropsychopharmacol sourceExperimental — accuracy not yet measured
The AEs section reports that 61%–75% of patients across treatment groups experienced at least one adverse event during the six-week treatment period, not around 30%. The paper does not establish the claimed similarity to previous studies. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Its blockage of the 5-HT3 receptors would improve the glutamatergic and serotoninergic transmission and also the firing of pyramidal neurons in prefrontal cortex, which plays a key role in the cognitive improvement.43”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Discussion
What the sources say
- Partly supportedcites [43] Pehrson, 2014, CNS Spectr sourceExperimental — accuracy not yet measured
The 5-HT3 receptors section (page unavailable) says antagonism can enhance glutamate transmission by reducing GABA-mediated inhibition; it reports increased pyramidal-cell firing in the rat hippocampus, while the prefrontal-cortex evidence concerns suppression of firing by 5-HT3 activation. The Multimodal Antidepressants section (page unavailable) identifies vortioxetine as a 5-HT3 antagonist and hypothesizes that its broader receptor profile could enhance glutamate transmission and cognition. It does not establish that vortioxetine’s 5-HT3 blockade improves serotonergic transmission or prefrontal pyramidal firing, or that this specific pathway is key to its cognitive effects. (LLM, conf=0.86)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At baseline, MDD patients had defects in Speed of Processing, Attention Vigilance, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition, compared with healthy controls.”
- Also stated in: § Discussion · plain
“In our study, MDD patients showed cognitive impairments compared with healthy individuals, including: Speed of Processing, Attention Vigilance, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition (Table 1).”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with before treatment, there were no differences in the scores of seven factors in MCCB between the two groups after 8 weeks of treatment, with all P3 > 0.05.”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Results > Cognitive Function Between the Two Groups
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 8 weeks of treatment with Vortioxetine or Escitalopram, the patients had improved in the aspects of cognitive functions above except Social Cognition.”
- Also stated in: § Discussion · hedged
“our study found that after 8 weeks of treatment, both Vortioxetine and Escitalopram could improve cognitive symptoms, but there was no statistical difference between the two antidepressants.”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · hedged
24 more claims
Create a free account to see all 67 claims and to verify the 2 references still open.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 20
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Abstract > Results
“After 8 weeks of treatment with Vortioxetine or Escitalopram, the patients had improved in the aspects of cognitive functions above except Social Cognition.”
§ A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality > Results > Cognitive Function Between the Two Groups
“The significant improvements of Attention Vigilance (45.15 vs 50.31), Speed of Processing (39.73 vs 47.65), Working Memory (39.78 vs 45.22), Verbal Learning (40.26 vs 47.19), and Reasoning and Problem Solving (41.70 vs 48.67) were discovered in the Vortioxetine group after the 8-week treatment (P1 < 0.05).”
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
Prevalence of mental disorders in China: a cross-sectional epidemiological study
Huang, Y., Wang, Y., Wang, H., Liu, Z., Yu, X., Yan, J., Yu, Y., Kou, C., Xu, X., Lu, J., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30511-x · Cited by 2,335
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Increased global integration in the brain after psilocybin therapy for depression
(2022) · doi:10.1038/s41591-022-01744-z · Cited by 445
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
von Rotz, R., Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101809 · Cited by 354
Cognitive Impairment in Major Depressive Disorder
Pan, Z., Park, C., Brietzke, E., Zuckerman, H., Rong, C., Mansur, R. B., Fus, D., Subramaniapillai, M., Lee, Y., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852918001207 · Cited by 320
Cited by
Pugh, D., Saunders, R., Jones, A., Dunn, B. D., & Buckman, J. E. J. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120165 · Cited by 8
Vaishnavi, V., Kumar, T. P., Valluru, R., Syamala, Y., Siva, C., & Bhavana, R. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.3549
Xin, L.-M., Fan, H.-Z., Lin, J., Yan, F., Yu, X. H., Su, Y. G., & Si, T. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122147
Metadata
- Authors
- Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., & Huang, M.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Corresponding author
- Huang, Manli
- ORCID
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2024-12
- Volume
- Volume 20
- Pages
- 2363-2374
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC11626980
- OpenAlex
- W4405083566
- Cited by
- 3
- References
- 58
- Citations by year
- 2026: 2 · 2025: 1
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- National Natural Science Foundation of China (2023C03077, 82271562)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- vortioxetine, escitalopram, major depressive disorder, cognitive function, antidepressant efficacy, adverse events, social cognition, Chinese Han patients, MATRICS Consensus Cognitive Battery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. https://app.cochat.ai/papers/10.2147/ndt.s491768
- The paper
- Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., & Huang, M. (2024). A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s491768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.